WO2004005336A3 - β-SHEET BREAKING PEPTIDES - Google Patents

β-SHEET BREAKING PEPTIDES Download PDF

Info

Publication number
WO2004005336A3
WO2004005336A3 PCT/EP2003/050287 EP0350287W WO2004005336A3 WO 2004005336 A3 WO2004005336 A3 WO 2004005336A3 EP 0350287 W EP0350287 W EP 0350287W WO 2004005336 A3 WO2004005336 A3 WO 2004005336A3
Authority
WO
WIPO (PCT)
Prior art keywords
sheet breaking
peptides
breaking peptides
dementia
sheet
Prior art date
Application number
PCT/EP2003/050287
Other languages
French (fr)
Other versions
WO2004005336A2 (en
Inventor
Claudio Soto-Jara
Celine Adessi
Serge Halazy
Thomas Rueckle
Original Assignee
Applied Research Systems
Claudio Soto-Jara
Celine Adessi
Serge Halazy
Thomas Rueckle
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems, Claudio Soto-Jara, Celine Adessi, Serge Halazy, Thomas Rueckle filed Critical Applied Research Systems
Priority to AU2003271745A priority Critical patent/AU2003271745A1/en
Priority to EP03753576A priority patent/EP1532170A2/en
Priority to CA002489754A priority patent/CA2489754A1/en
Priority to JP2004518784A priority patent/JP2006508904A/en
Publication of WO2004005336A2 publication Critical patent/WO2004005336A2/en
Publication of WO2004005336A3 publication Critical patent/WO2004005336A3/en
Priority to IL16610205A priority patent/IL166102A0/en
Priority to NO20050436A priority patent/NO20050436D0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Provided are peptides having Beta-sheet breaking ability, based on the requeme LPFFD, useful in the treatment and prevention of diseases such as Alzheimer's disease, Dementia pugilistica (including head trauma), hereditary Cerebral Haemorrhage with amyloidosis of the Dutch type (HCHWA-D) and vascular dementia with amyloid angiopathy.
PCT/EP2003/050287 2002-07-08 2003-07-07 β-SHEET BREAKING PEPTIDES WO2004005336A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU2003271745A AU2003271745A1 (en) 2002-07-08 2003-07-07 Beta-SHEET BREAKING PEPTIDES
EP03753576A EP1532170A2 (en) 2002-07-08 2003-07-07 Beta-sheet breaking peptides
CA002489754A CA2489754A1 (en) 2002-07-08 2003-07-07 .beta.-sheet breaking peptides
JP2004518784A JP2006508904A (en) 2002-07-08 2003-07-07 β-sheet breaking peptide
IL16610205A IL166102A0 (en) 2002-07-08 2005-01-03 Beta-sheet breaking peptides and their use
NO20050436A NO20050436D0 (en) 2002-07-08 2005-01-26 Beta-layer-breaking peptides

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP02100787.7 2002-07-08
EP02100787 2002-07-08
EP02102834.5 2002-12-19
EP02102834 2002-12-19

Publications (2)

Publication Number Publication Date
WO2004005336A2 WO2004005336A2 (en) 2004-01-15
WO2004005336A3 true WO2004005336A3 (en) 2004-02-26

Family

ID=30116915

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/050287 WO2004005336A2 (en) 2002-07-08 2003-07-07 β-SHEET BREAKING PEPTIDES

Country Status (7)

Country Link
EP (1) EP1532170A2 (en)
JP (1) JP2006508904A (en)
AU (1) AU2003271745A1 (en)
CA (1) CA2489754A1 (en)
IL (1) IL166102A0 (en)
NO (1) NO20050436D0 (en)
WO (1) WO2004005336A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130065042A1 (en) 2011-03-11 2013-03-14 The Board Of Trustees Of The University Of Illinois Micro-Vascular Materials And Composites For Forming The Materials
SG187271A1 (en) * 2011-07-07 2013-02-28 Agency Science Tech & Res Anti-amyloidogenic, alpha-helix breaking ultra-small peptide therapeutic

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001007473A1 (en) * 1999-07-28 2001-02-01 Kelvin Stott Peptides containing n-substituted l-amino acids for preventing beta-strand association
WO2001034631A2 (en) * 1999-11-05 2001-05-17 Axonyx, Inc. PEPTIDE ANALOGS AND MIMETICS SUITABLE FOR IN VIVO USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH ABNORMAL PROTEIN FOLDING INTO AMYLOID, AMYLOID-LIKE DEPOSITS OR β-SHEET RICH PATHOLOGICAL PRECURSOR THEREOF

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001007473A1 (en) * 1999-07-28 2001-02-01 Kelvin Stott Peptides containing n-substituted l-amino acids for preventing beta-strand association
WO2001034631A2 (en) * 1999-11-05 2001-05-17 Axonyx, Inc. PEPTIDE ANALOGS AND MIMETICS SUITABLE FOR IN VIVO USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH ABNORMAL PROTEIN FOLDING INTO AMYLOID, AMYLOID-LIKE DEPOSITS OR β-SHEET RICH PATHOLOGICAL PRECURSOR THEREOF

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ADESSI CÉLINE ET AL: "Pharmacological profiles of peptide drug candidates for the treatment of Alzheimer's disease.", THE JOURNAL OF BIOLOGICAL CHEMISTRY. UNITED STATES 18 APR 2003, vol. 278, no. 16, 18 April 2003 (2003-04-18), pages 13905 - 13911, XP002265907, ISSN: 0021-9258 *
PERMANNE BRUNO ET AL: "Reduction of amyloid load and cerebral damage in a transgenic mouse model of Alzheimer's disease by treatment with a beta-sheet breaker peptide.", THE FASEB JOURNAL: OFFICIAL PUBLICATION OF THE FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY. UNITED STATES JUN 2002, vol. 16, no. 8, June 2002 (2002-06-01), pages 860 - 862, XP002265906, ISSN: 1530-6860 *
SOTO C ET AL: "INHIBITION OF ALZHEIMER'S AMYLOIDOSIS BY PEPTIDES THAT PREVENT BETA-SHEET CONFORMATION", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 226, no. 3, 24 September 1996 (1996-09-24), pages 672 - 680, XP002050229, ISSN: 0006-291X *
WEINSTEIN B: "CHEMISTRY AND BIOCHEMISTRY OF AMINO ACIDS, PEPTIDES AND PROTEINS, PASSAGE", CHEMISTRY AND BIOCHEMISTRY OF AMINO ACIDS, PEPTIDES, AND PROTEINS, XX, XX, VOL. 7, PAGE(S) 266-357, XP002032461 *

Also Published As

Publication number Publication date
NO20050436L (en) 2005-01-26
CA2489754A1 (en) 2004-01-15
AU2003271745A1 (en) 2004-01-23
JP2006508904A (en) 2006-03-16
EP1532170A2 (en) 2005-05-25
NO20050436D0 (en) 2005-01-26
WO2004005336A2 (en) 2004-01-15
IL166102A0 (en) 2006-01-15

Similar Documents

Publication Publication Date Title
WO2004074232A8 (en) 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
EP1769791A3 (en) Treatment of Alzheimer's disease with cell cycle inhibitors
WO2002088101A3 (en) Inhibitors of bace
WO2001078709A3 (en) Treatment of neurodegenerative disease
WO2000072876A3 (en) Prevention and treatment of amyloidogenic disease
WO2007021886A3 (en) Truncated memapsin 2 for use for treating alzheimer's disease
WO2002096415A3 (en) Use of azetidinone substituted derivatives in the treatment of alzheimer's disease
WO2003039454A8 (en) Beta-secretase inhibitors and methods of use
AU2002335794A1 (en) Allylamides useful in the treatment of alzheimer's disease
AU2003231252A1 (en) Methods and compositions for the treatment and prevention of intermittent claudication or alzheimer's disease
NO20053237L (en) Azapeptide.
MY139368A (en) Novel cyclohexyl sulphones
WO2004082706A3 (en) Ifn-beta alone or in combination with other medicaments for treating alzheimer's disease and demens disorders
NO20053341D0 (en) Prevention and treatment of Alzheimer's disease.
WO2002100836A8 (en) Compounds, compositions and methods for modulating beta-amyloid production
WO2004026258A3 (en) Modulating vesicular monoamine transporter trafficking and function: a novel approach for the treatment of parkinson’s disease
AU2003248660A1 (en) Treatment of vascular dysfunction and alzheimer's disease
WO2004005336A3 (en) β-SHEET BREAKING PEPTIDES
WO2004066940A3 (en) Compositions and methods containing substituted quinolines and substituted diphenylsulfones
WO2004096845A3 (en) Beta-amyloid inhibitors and use thereof
WO2002099061A3 (en) Method of treating alzheimer's disease with se-containing peptide
WO2004097358A3 (en) Diagnostics and therapeutics for diseases associated with human transmembrane serine protease 2 (tmprss2)
AU2003286530A1 (en) Substituted peptides useful in the treatment of alzheimer's disease
WO2001010428A3 (en) Use of n-methyl bases of ethanolamine for prevention of cell death induced by oxidative stress
WO2005025590A3 (en) Use of a dg280 protein product for preventing and treating metabolic disorders

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003271745

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2489754

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 166102

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2004518784

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003753576

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003753576

Country of ref document: EP